mevastatin has been researched along with Hypertension in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Duriez, P; Fruchart, JC; Hazzan, M; Kandoussi, A; Martin, F; Noël, C; Staels, B | 1 |
Dong, J; Fujii, S; Furumoto, T; Goto, D; Imagawa, S; Kaneko, T; Kitabatake, A; Mishima, T; Nakai, Y; Zaman, TA | 1 |
2 other study(ies) available for mevastatin and Hypertension
Article | Year |
---|---|
HMG-CoA reductase inhibition and PPAR- alpha activation both inhibit cyclosporin A induced endothelin-1 secretion in cultured endothelial cells.
Topics: Animals; Aorta; Cattle; Cells, Cultured; Clofibric Acid; Cyclosporine; Endothelin-1; Endothelium, Vascular; Fibric Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Lovastatin; Mevalonic Acid; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2002 |
Increased expression of plasminogen activator inhibitor-1 by mediators of the acute phase response: a potential progenitor of vasculopathy in hypertensives.
Topics: Acute-Phase Reaction; Blotting, Northern; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Interleukin-1; Interleukin-6; Liver Neoplasms; Lovastatin; Mevalonic Acid; Plasminogen Activator Inhibitor 1; RNA, Messenger; Up-Regulation | 2003 |